S. Duvert-Lehembre

发表

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.

O. Dereure, M. Richard, G. Jeudy, 2019, The Journal of investigative dermatology.

Clinical and immunological features and outcome of anti‐p200 pemphigoid

P. Stoebner, E. Schmidt, P. Joly, 2016, The British journal of dermatology.

Drug‐induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases

M. Beylot-Barry, G. Jeudy, V. Descamps, 2019, British journal of clinical pharmacology.

Trimethoprim-sulfamethoxazole-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

C. Lok, G. Chaby, S. Duvert-Lehembre, 2017, Dermatology online journal.

Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid.

F. Antonicelli, C. Prost-Squarcioni, P. Bernard, 2013, JAMA dermatology.

Sensitivity and specificity of BP180 NC16A enzyme‐linked immunosorbent assay for the diagnosis of pemphigoid gestationis

B. Darwish, V. Hébert, P. Joly, 2017, Journal of the American Academy of Dermatology.

Incidence and mortality of bullous pemphigoid in France.

P. Courville, A. Sparsa, V. Doffoel-Hantz, 2012, The Journal of investigative dermatology.

Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids.

E. Houivet, M. D’Incan, P. Joly, 2013, Journal of the American Academy of Dermatology.

Assessment of hydro-saline retention in bullous pemphigoid patients treated with super-potent topical corticosteroids.

V. Hébert, S. Duvert-Lehembre, A. Deschamps-Huvier, 2022, Annales de dermatologie et de venereologie.

International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut‐off values for defining mild, moderate and severe types of bullous pemphigoid *

C. Moltrasio, P. Plantin, C. Prost-Squarcioni, 2020, The British journal of dermatology.

The Regibul Register: A Tool for Monitoring the Distribution and Incidence of Autoimmune Bullous Dermatoses in Three French Regions, 2010 to 2015.

P. Bernard, P. Joly, C. Barbe, 2018, Acta dermato-venereologica.

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

L. Misery, A. Dupuy, O. Dereure, 2020, JAMA dermatology.

Incidence and Mortality of Pemphigus in France.

L. Misery, A. Dupuy, L. Verneuil, 2019, The Journal of investigative dermatology.

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

L. Misery, O. Dereure, N. Dupin, 2017, The Lancet.